Daily summary: European shares decline in quiet trading session

7:31 pm 3 July 2020

• COVID-19 has mutated to become more easily transmissible
• 40 US states reported rising number of COVID-19 cases
• Gilead's
(GILD.US) antiviral drug remdesivir approved by EU

It was a largely quiet session with nothing much for traders to work with, considering that US markets are closed in observance of the 4th of July festivities. Major European indices finished last session of the week in red amid lower liquidity. DAX lost 0.8 %, CAC 40 dropped 1.1 % and FTSE 100 finished 1.5 % lower. For the week,  DAX climbed 3.6%,  CAC 40 rose 2%, FTSE 100 remain unchanged.
 
European indexes started the session on positive note supported by better than expected Chinese PMI reading which signaled the fastest increase in service activity for over a decade. However recent PMI data from the Eurozone showed that the private sector activity continues to decline despite the fact that most countries have lifted coronavirus-related restrictions.
 
In addition, concerns about a second wave of infections mounted as well as its impact on the global economic recovery after United States reported more than 55,000 new COVID-19 cases, setting a third record in a row. The daily US tally stood at 55,274 late Thursday, which exceeds the previous single-day record of 54,771 set by Brazil on June 19. Also according to some reports coronavirus cases are rising in 40 out of 50 states across the country now. Florida's is one of the worst-affected regions. Yesterday the state Department of Heath reported  another daily record, with 10 109 cases, surpassing Saturday's record of 9 585 cases. In order to contain spread of the virus many US states ordered citizens to wear masks in public.
 
Meantime WHO expert Van Kerkhove cited it in today's briefing that coronavirus may have mutated to become more infectious, however  he also noted that there's no evidence that it's more  or less dangerous.
 
Today European Commission  given conditional approval for the use of Gilead's (GILD.US) antiviral remdesivir in severe COVID-19 patients following an accelerated review process, making it the region's first authorized therapy to treat the virus. "We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus," said Stella Kyriakides, EU Commissioner for Health and Food Safety, in a statement.
 
Now investors will try to assess whether rising number of infections will cause fear among the general population and negatively impact consumer spending and consumption. If this happens, then financial markets would find themselves under severe pressure.
 
On the commodities front, spot gold traded at $1,775 per ounce today close to the eight-year high of $1,789 reached on Wednesday, while Oil prices fell around 1%.
 
Economic calendar for Monday does not seem to be particularly interesting. German Factory Orders  will be the key release of the European session while US ISM Non-Manufacturing PMI will be on watch during US trading hours. Apart from that  investors will get to know New Zealand Business Confidence reading. Of course, news regarding the spread of the coronavirus should have the biggest impact on the markets.
USDCHF continues to swing within a 0.9422 -0.9547 range. Yesterday currency pair tested lower limit of the range but failed to break below. Bullish divergence occurred on the Momentum indicator, which might be a sign that sell-off  run out of steam. However if sellers will manage to break below the support at 0.9422 then 0.9374 level may be at risk. Source: xStation5

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.

Share:
Back
Xtb logo

Join over 935 000 XTB Group Clients from around the world.

We use cookies

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

This group contains cookies that are necessary for our websites to work. They take part in functionalities like language preferences, traffic distribution or keeping user session. They cannot be disabled.

Cookie name
Description
SERVERID
userBranchSymbol cc 2 March 2024
adobe_unique_id cc 1 March 2025
__hssc cc 8 September 2022
SESSID cc 2 March 2024
__cf_bm cc 8 September 2022
intercom-id-iojaybix cc 26 November 2024
intercom-session-iojaybix cc 8 March 2024

We use tools that let us analyze the usage of our page. Such data lets us improve the user experience of our web service.

Cookie name
Description
__hstc cc 7 March 2023
__hssrc

This group of cookies is used to show you ads of topics that you are interested in. It also lets us monitor our marketing activities, it helps to measure the performance of our ads.

Cookie name
Description
hubspotutk cc 7 March 2023

Cookies from this group store your preferences you gave while using the site, so that they will already be here when you visit the page after some time.

Cookie name
Description

This page uses cookies. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. For more information see our Privacy Policy You can manage cookies by clicking "Settings". If you agree to our use of cookies, click "Accept all".

Change region and language
Country of residence
Language